Pharma Watch

Leading Pharma Leading Pharma

Challenged Pharma Challenged Pharma

Sarepta Receives Complete Response Letter from FDA for DMD Treatment

Sarepta Receives Complete Response Letter from FDA for DMD Treatment

Sarepta Therapeutics announced it has received a Complete Response Letter (CRL) from the U.S. FDA regarding a New Drug Application (NDA) seeking accelerated approval of golodirsen injection for the treatment of Duchenne muscular dystrophy (DMD) in patients with a...

subscribe

CNS Summit
subscribe

Pin It on Pinterest